ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 626,54
0,21%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCC)

  7. Cyclacel Pharmaceuticals Inc (CYCC) Actualités

CYCC

Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYCC
DateHeureSourceTitreSymboleSociété
14/05/202422h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/05/202422h30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202419h51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202413h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/04/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/02/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/01/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
18/12/202315h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
12/12/202322h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/11/202315h15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCCyclacel Pharmaceuticals Inc
28/11/202323h15GlobeNewswire Inc.Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/11/202315h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
09/08/202322h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/08/202315h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
11/05/202323h16Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/05/202315h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/05/202315h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/03/202323h03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/02/202322h56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/02/202317h27Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/02/202322h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
16/08/202214h01Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
17/06/202222h07Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCC

Dernières Valeurs Consultées

BIT
UC3QL9
Unicredit Bank
EU
C491S
C491S
NYSE
MNR.PRBCL
Monmouth Real Estate Investment
BIT
F18340
Vontobel Financial Produ...
BOV
ABUD34
Anheuser-Busch In Bev SA...
BIT
F09703
Vontobel Financial Produ...
COIN
ACUST
ACoconut
COIN
BTSGUSD
BitSong
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés